Claims that a 'game-changing' new drug can drastically slow mental decline are overblown, scientists warned today.Donanemab can thwart the memory-robbing disease's progression by up to 60 per cent, US pharma giant Eli Lilly said yesterday when unveiling final trial results. But the figures on its effectiveness are based on patient test results from an Alzheimer's assessment, taken at the beginning and end of an 18-month study.
Load More
Load More